It aims to achieve the maximum value of commercialization beyond the industry average by empowering global innovative drug new technologies, combining its own accumulated many conversion channels and capital advantages, meeting the global unmet clinical needs, benefiting patients and giving back to shareholders. The company adopts the introduction and self-development two-wheel drive model, and a richer product pipeline will be approved in the next two years.